NCT03186053

Brief Summary

To explore the effect of intraoperative sodium creatine phosphate on myocardial protection in patients undergoing valve surgery

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
250

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Jun 2017

Geographic Reach
1 country

2 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 29, 2017

Completed
16 days until next milestone

First Posted

Study publicly available on registry

June 14, 2017

Completed
1 day until next milestone

Study Start

First participant enrolled

June 15, 2017

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2018

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2018

Completed
Last Updated

January 31, 2018

Status Verified

January 1, 2018

Enrollment Period

1 year

First QC Date

May 29, 2017

Last Update Submit

January 30, 2018

Conditions

Outcome Measures

Primary Outcomes (1)

  • serum cardiac troponin I(cTnI)

    serum cardiac troponin I(cTnI)

    within 24 hours after aortic declamping

Secondary Outcomes (6)

  • mortality

    within 30 postoperative days

  • stroke

    within 30 postoperative days

  • blood filtration of kidney failure

    within 30 postoperative days

  • extracorporeal membrane oxygenation (ECMO) or intraaortic balloon counterpulsation (IABP) support

    within 30 postoperative days

  • mechanical ventilation time

    within 30 postoperative days

  • +1 more secondary outcomes

Study Arms (2)

sodium creatine phosphate

EXPERIMENTAL

5g creatine phosphate was dissolved in 50ml saline solution. After induction of anesthesia, the patients were first given a load dose of 1g, 20min (30ml / h) , And then pumped at a rate of 1 g / h (10 ml / h).

Drug: sodium creatine phosphate

Control

PLACEBO COMPARATOR

The control group was treated with saline in the same manner.

Drug: saline

Interventions

sodium creatine phosphate .Loading dose followed by continuous infusion in operation

Also known as: Neoton
sodium creatine phosphate
salineDRUG

.Loading dose followed by continuous infusion in operation

Control

Eligibility Criteria

Age18 Years - 70 Years
Sexall(Gender-based eligibility)
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • valvular disease patients requiring valvular replacement or repair surgery with cardiopulmonary bypass(CPB)

You may not qualify if:

  • thoracoscopic valve surgery
  • other organ dysfunction: such as cancer, organ failure, severe anemia, infection
  • patients with mental disorders
  • coagulopathy, active ulcer, ischemic or hemorrhagic stroke (within 6 months), trauma

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Department of Anesthesiology ,Fuwai Hospital, National Center for Cardiovascular Diseases, CAMS and PUMC

Beijing, Beijing Municipality, 100037, China

RECRUITING

Cardiovascular Institute and Fuwai Hospital

Beijing, 100037, China

RECRUITING

MeSH Terms

Conditions

Heart Valve Diseases

Interventions

PhosphocreatineSodium Chloride

Condition Hierarchy (Ancestors)

Heart DiseasesCardiovascular Diseases

Intervention Hierarchy (Ancestors)

CreatineAmino AcidsAmino Acids, Peptides, and ProteinsPhosphoamino AcidsChloridesHydrochloric AcidChlorine CompoundsInorganic ChemicalsSodium Compounds

Study Officials

  • Guyan WANG, M.D.

    Department of anesthesiology,Fuwai hospital

    STUDY DIRECTOR

Central Study Contacts

Guyan WANG, M.D.

CONTACT

Zhongrong FANG, M.D

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
The Chief of Infection-Control Department

Study Record Dates

First Submitted

May 29, 2017

First Posted

June 14, 2017

Study Start

June 15, 2017

Primary Completion

July 1, 2018

Study Completion

December 31, 2018

Last Updated

January 31, 2018

Record last verified: 2018-01

Data Sharing

IPD Sharing
Will not share

Locations